A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer.
A randomized, prospective blind study was carried out to investigate the need for luteal phase support in patients undergoing in-vitro fertilization (IVF). One-hundred-and-fifty-six patients undergoing IVF in cycles stimulated with human menopausal gonadotropin (HMG) and human chorionic gonadotrophin (HCG) stimulated IVF, were divided into three different groups for luteal phase treatment. Fifty-four patients received dydrogesterone three times daily (TID) beginning on the day of embryo transfer (ET). Fifty-one patients received HCG on days 3, 6 and 10 following ET. Fifty-one patients received placebo p.o. TID beginning on the day of ET. There was no difference between the groups in pregnancy rate, rate of spontaneous abortion, proportion of normally developing fetuses or rate of chemical pregnancy. The data indicate that supplementation of the luteal phase may not improve the success rates of IVF-ET cycles.
Kupferminc
M J
MJ
IVF Unit, Serline Maternity Hospital, Sakler School of Medicine, Tel-Aviv University, Israel.
Lessing
J B
JB
Amit
A
A
Yovel
I
I
David
M P
MP
Peyser
M R
MR
D000328:Adult; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D004394:Dydrogesterone / Q000494:pharmacology*; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro / Q000187:drug effects*; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects; D011247:Pregnancy / Q000187:drug effects*; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies
D006063:Chorionic Gonadotropin; D011374:Progesterone; D004394:Dydrogesterone